Your BMI reads "normal," your clothes fit, and a scale tells you nothing is wrong. Yet a growing body of Indian research shows that many people who look metabolically healthy are carrying a deep, hidden fat depot that raises their risk of diabetes and heart disease. That depot is visceral fat: the fat packed around your abdominal organs. It is more strongly linked to insulin resistance than the fat under your skin, and in South Asians it tends to build up at lower body weights. This page explains what it is, why it matters, and how it is measured.

• Visceral fat is stored inside the abdominal cavity around the organs, and is distinct from the subcutaneous fat you can pinch under the skin.
• It is more strongly linked to insulin resistance, type 2 diabetes, and heart disease than subcutaneous fat is, through both inflammatory and metabolic pathways.
• At the same BMI, South Asian adults tend to carry more visceral fat and become insulin resistant at lower body weights than Europeans.
• Keeping your waist under half your height (waist-to-height ratio below 0.5) is the most practical home screen for visceral fat risk.
• Consumer smart scales have no validated accuracy for visceral fat in Indian adults. Their readings are rough trends, not clinical measurements.

Visceral adipose tissue is intra-abdominal fat stored inside the abdominal cavity, wrapped around the internal organs within the omentum, mesentery, and peri-organ spaces. It is distinct from subcutaneous fat, the layer that sits between the skin and the abdominal wall, and from ectopic fat, which is abnormal fat stored inside organs such as the liver, pancreas, and muscle.

Ectopic fat deserves its own mention because it matters clinically. When fat accumulates inside the liver it becomes fatty liver disease. Inside the pancreas it can impair insulin secretion. Inside skeletal muscle it reduces insulin sensitivity in the tissue responsible for most glucose disposal in the body. Visceral, subcutaneous, and ectopic fat are three different problems with different clinical consequences, even though all three tend to accumulate together in people who carry excess abdominal fat.

The "belly fat" you can see or pinch is a mixture of subcutaneous and visceral fat, and only imaging can separate the two. Someone with a flat-looking abdomen can still carry a substantial visceral load, which is why appearance is an unreliable guide.

Visceral fat is more closely associated with insulin resistance, type 2 diabetes, and cardiovascular disease than subcutaneous fat is. Two mechanisms are usually offered to explain the difference, and both are worth stating at their real confidence level.

The portal free-fatty-acid hypothesis proposes that visceral fat drains directly into the portal vein, exposing the liver to higher concentrations of fatty acids and driving hepatic insulin resistance. Animal and human physiology studies support parts of this model, but it is partly contested: some researchers argue that fat inside the liver and muscle correlates with insulin resistance better than total visceral fat mass does.

The second mechanism is the inflammatory pathway. Visceral fat is more metabolically active than subcutaneous fat, secreting higher levels of pro-inflammatory signals such as IL-6 and TNF-alpha and less of the protective adipokine adiponectin. This low-grade inflammation is a plausible bridge from visceral adiposity to metabolic and cardiovascular disease, though most of the evidence is associational rather than from controlled trials.

South Asians tend to store more visceral and ectopic fat, and to become insulin resistant, at body weights that Western charts would call fine. In one foundational study of Asian Indian men, an average BMI of 24.5 corresponded to 33% body fat, of which 16% was visceral, and two-thirds of these non-obese men were insulin resistant. Later imaging work found that non-obese North-Indian adults with type 2 diabetes carried roughly 50% more intra-abdominal fat than matched controls of similar BMI.

One explanation is limited subcutaneous storage capacity. When the "safe" fat compartment under the skin fills up, excess lipid is diverted into visceral and ectopic depots, a pattern sometimes described as the thin-fat or normal-weight metabolic risk phenotype. An unpublished 2025 conference abstract on a Gujarat cohort reported that about 45% of normal-BMI participants had elevated visceral fat on DEXA. As a poster rather than a peer-reviewed paper, it points to the size of the problem without settling it. The practical takeaway is consistent across better-established studies: BMI alone is an unreliable screen for Indians.

This is part of the reason Indian clinical guidance uses lower BMI and waist thresholds than the global standard.

The pattern is not identical across all Indian adults. For Indian women, the point at which visceral fat becomes clinically significant shifts with life stage. Polycystic ovary syndrome (PCOS) can drive visceral fat accumulation well before conventional weight thresholds are crossed, and studies of Indian women with PCOS consistently find elevated visceral fat at normal BMI compared with BMI-matched peers without the condition. After menopause, the redistribution of body fat from peripheral to central stores is a documented physiological change, and this accelerated visceral gain has been observed in Indian women at BMI levels that would not otherwise prompt clinical concern.

Measurement methods differ widely in accuracy, and consumer devices are the weakest link.

CT and MRI: Reference Standard

What it measures: Directly image the visceral fat depot.

Reliability: CT and MRI agree closely and are considered the reference standard for measuring visceral fat. Their cost, and radiation exposure with CT, limit routine use.

DEXA: Validated Surrogate

What it measures: Estimates visceral fat in the abdominal region.

Reliability: DEXA correlates well with MRI and is a validated alternative, although its estimates can become less precise at very high or low visceral fat volumes.

Waist Circumference and Waist-to-Height Ratio

What they measure: Body measurements as proxies for abdominal fat.

Reliability: They are inexpensive and practical. A waist-to-height ratio below 0.5 is a useful reference point, with higher values flagging elevated risk.

Smart Scales and Consumer BIA

What they measure: Provide a modelled "visceral fat rating" based on body-composition estimates.

Reliability: There is no published validation against CT or MRI in Indian adults. These readings should therefore be treated as a rough trend rather than a clinical measurement.

For most people, waist measures are the sensible starting point: keeping your waist under half your height is a simple screen, and the specific Indian waist cut-offs are covered separately. A home scale's visceral fat score is not a clinical measurement and should not be read as reassurance. Imaging is reserved for cases where a clinician decides the added precision will change a decision.

The honest answer is that you cannot target it in isolation. No non-pharmacological approach has been shown to melt visceral fat while leaving other fat unchanged, and "spot reduction" through crunches or core work is not supported by evidence. What the research does show is that visceral fat is often particularly responsive to sustained activity and that reducing it does not require large changes on the scale.

The three most consistently evidenced approaches, in order of how directly they affect the visceral depot, are:

1. Sustained aerobic exercise: A 2012 meta-analysis of randomised trials found that aerobic exercise produced a significant reduction in visceral fat, while resistance training alone did not. Imaging research shows that visceral fat can shrink meaningfully even when overall body weight changes little, suggesting the depot responds to aerobic activity before total weight loss is visible.
2. Overall caloric deficit through diet: Diet-driven weight loss reduces visceral and subcutaneous fat together rather than targeting one compartment. You cannot direct where the reduction comes from, but both depots shrink as total energy balance turns negative.
3. Protecting sleep: Short sleep is linked to visceral fat accumulation over time. Consistently inadequate sleep is not just a wellbeing issue but a driver of the very fat depot this article is about.

The clinical picture is straightforward: lose fat through sustained aerobic activity, a sensible diet, and adequate sleep, and your visceral fat will almost certainly fall, often faster than fat elsewhere. You are shrinking the whole system, not draining one tank.

Because visible size is such a poor guide to visceral risk, a structured body-composition assessment with a Voy clinician can tell you what a mirror cannot, and put any numbers in the context of your wider metabolic health. Any decision about testing or treatment belongs with a registered medical practitioner, not a scale or an article.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.